On Feb. 27, 2026, the European Medicines Agency (EMA) announced it’s recommending marketing authorization for mCombriax, Moderna’s combined mRNA vaccine for protecting older adults against COVID-19 and flu. This recommendation was announced with 11 other medicines approved at its February 2026 meeting.

According to data released by the World Health Organization (WHO), as of 1 February 2026, there had been 281,728,062 cases of COVID-19 reported in Europe. Seasonal influenza also presents a significant burden, with up to 50 million symptomatic cases of seasonal influenza occurring every year in the European Economic Area (EEA).

The recommendation was made by the EMA’s Committee for Medicinal Products for Human Use (CHMP), which looked at data from a phase 3 trial involving 8,000 participants aged 50 and older. The results of that trial showed participants who received mCombriax (mRNA-1083) had non-inferior immune responses to those who received Moderna’s licensed COVID-19 vaccine (Spikevax) or authorized high- or standard-dose flu vaccines (Fluzone and Fluarix).